Jubilant Pharma early redeems $100 million of 4 7/8% notes due 2021

By Marisa Wong

Los Angeles, Feb. 1 – Jubilant Pharma Ltd. announced the early redemption of $100 million of its 4 7/8% senior notes due 2021 (ISIN: XS1493722299) on Jan. 29, according to an announcement.

The notes were redeemed on a pro rata basis at 101.21875 plus accrued interest.

Following the redemption, the outstanding amount of the notes is $100 million.

Jubilant Pharma had redeemed $100 million of the original $300 million principal amount in November 2019.

The issuer is a Singapore-based subsidiary of Indian pharmaceutical company Jubilant Life Sciences Ltd.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.